Drug-induced hepatitis after Sinopharm COVID-19 vaccination: A case study of a 62-year-old patient

Ghorbani, Hossein; Rouhi, Tina; Vosough, Zeinab; Shokri-shirvani, Javad

doi:10.1016/j.ijscr.2022.106926

Cited by 18 publications

(15 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several cases of hepatitis have been reported after COVID-19 vaccines, but most of them were diagnosed as vaccine-triggered AIH. Although DIH cases following COVID-19 vaccination have also been reported before, to our best knowledge, the present study is the first report of the DIH occurrence following both the first and second dose of the Sinopharm COVID-19 vaccine and only second to [7] to report hepatitis following administration of this vaccine.…”

Section: Discussionsupporting

confidence: 53%

“…So far, COVID-19 vaccination has been associated with the development of various liver disorders, such as autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC), presumably through cross-reactivity with host cells [3] , [4] , [5] . Additionally, several studies have reported cases of DIH following Pfizer-BioNTech [6] and Sinopharm [7] SARS-CoV-2 vaccination. Herein, we reported another case of DIH following Sinopharm COVID-19 vaccination in a 34-year-old female patient.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Drug-induced hepatitis (DIH) after SARS-CoV-2 vaccination

Asgarzdeh¹,

Habibzadeh²,

Asghariazar³

et al. 2023

Clinics and Research in Hepatology and Gastroenterology

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 53%

Section: Introductionmentioning

confidence: 99%

Drug-induced hepatitis (DIH) after SARS-CoV-2 vaccination

Asgarzdeh¹,

Habibzadeh²,

Asghariazar³

et al. 2023

Clinics and Research in Hepatology and Gastroenterology

View full text Add to dashboard Cite

“…Acute liver injuries (ALIs) was the fourth most-common disease (twenty-one cases) reported following COVID-19 vaccination from our review [sixteen new onset cases [12,13,44,99,113,122] and five relapsed cases [13]]…”

Section: Acute Liver Injurymentioning

confidence: 99%

“…(see Table 1). Most common clinical presentations in patients who presented with ALIs post-COVID-19 vaccination were abdominal tenderness (n = 3) [12,113], jaundice (n = 2) [44,113], yellow eyes (n = 2) [12,44], weakness (n = 2) [12,44], and vomiting (n = 2) [12,113].…”

Section: Acute Liver Injurymentioning

confidence: 99%

New-onset and relapsed liver diseases following COVID-19 vaccination: a systematic review

et al. 2022

View full text Add to dashboard Cite

Background Liver diseases post-COVID-19 vaccination is extremely rare but can occur. A growing body of evidence has indicated that portal vein thrombosis, autoimmune hepatitis, raised liver enzymes and liver injuries, etc., may be potential consequence of COVID-19 vaccines. Objectives To describe the results of a systematic review for new-onset and relapsed liver disease following COVID-19 vaccination. Methods For this systematic review, we searched Proquest, Medline, Embase, PubMed, CINAHL, Wiley online library, Scopus and Nature through the Preferred Reporting Items for Systematic Reviews and Meta Analyses PRISMA guideline for studies on the incidence of new onset or relapsed liver diseases post-COVID-19 vaccination, published from December 1, 2020 to July 31, 2022, with English language restriction. Results Two hundred seventy-five cases from one hundred and eighteen articles were included in the qualitative synthesis of this systematic review. Autoimmune hepatitis (138 cases) was the most frequent pathology observed post-COVID-19 vaccination, followed by portal vein thrombosis (52 cases), raised liver enzymes (26 cases) and liver injury (21 cases). Other cases include splanchnic vein thrombosis, acute cellular rejection of the liver, jaundice, hepatomegaly, acute hepatic failure and hepatic porphyria. Mortality was reported in any of the included cases for acute hepatic failure (n = 4, 50%), portal vein thrombosis (n = 25, 48.1%), splanchnic vein thrombosis (n = 6, 42.8%), jaundice (n = 1, 12.5%), raised liver enzymes (n = 2, 7.7%), and autoimmune hepatitis (n = 3, 2.2%). Most patients were easily treated without any serious complications, recovered and did not require long-term hepatic therapy. Conclusion Reported evidence of liver diseases post-COIVD-19 vaccination should not discourage vaccination against this worldwide pandemic. The number of reported cases is relatively very small in relation to the hundreds of millions of vaccinations that have occurred and the protective benefits offered by COVID-19 vaccination far outweigh the risks.

show abstract

“…There are several other reports of autoimmune hepatitis following mRNA or viral vector COVID-19 vaccines. Drug-induced hepatitis was also reported following the inactivated whole virus vaccine[ 171 ].…”

Section: Post-vaccination Autoimmune Disordersmentioning

confidence: 99%

COVID-19 disease and autoimmune disorders: A mutual pathway

Al‐Biltagi¹,

Saeed²,

Bediwy³

2022

WJM

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) is a real challenge for humanity with high morbidity and mortality. Despite being primarily a respiratory illness, COVID-19 can affect nearly every human body tissue, causing many diseases. After viral infection, the immune system can recognize the viral antigens presented by the immune cells. This immune response is usually controlled and terminated once the infection is aborted. Nevertheless, in some patients, the immune reaction becomes out of control with the development of autoimmune diseases. Several human tissue antigens showed a strong response with antibodies directed against many severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) proteins, such as SARS-CoV-2 S, N, and autoimmune target proteins. The immunogenic effects of SARS-CoV-2 are due to the sizeable viral RNA molecules with interrupted transcription increasing the pool of epitopes with increased chances of molecular mimicry and interaction with the host immune system, the overlap between some viral and human peptides, the viral induced-tissue damage, and the robust and complex binding between sACE-2 and SARS-CoV-2 S protein. Consequently, COVID-19 and its vaccine may trigger the development of many autoimmune diseases in a predisposed patient. This review discusses the mutual relation between COVID-19 and autoimmune diseases, their interactive effects on each other, the role of the COVID-19 vaccine in triggering autoimmune diseases, the factors affecting the severity of COVID-19 in patients suffering from autoimmune diseases, and the different ways to minimize the risk of COVID-19 in patients with autoimmune diseases.

show abstract

Drug-induced hepatitis after Sinopharm COVID-19 vaccination: A case study of a 62-year-old patient

Cited by 18 publications

References 18 publications

Drug-induced hepatitis (DIH) after SARS-CoV-2 vaccination

Drug-induced hepatitis (DIH) after SARS-CoV-2 vaccination

New-onset and relapsed liver diseases following COVID-19 vaccination: a systematic review

COVID-19 disease and autoimmune disorders: A mutual pathway

Contact Info

Product

Resources

About